↓ Skip to main content

Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting

Overview of attention for article published in Thrombosis Journal, May 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting
Published in
Thrombosis Journal, May 2016
DOI 10.1186/s12959-016-0084-2
Pubmed ID
Authors

Luigi Brunetti, Betty Sanchez-Catanese, Leonid Kagan, Xia Wen, Min Liu, Brian Buckley, James P. Luyendyk, Lauren M. Aleksunes

Abstract

Dabigatran etexilate may be underutilized in geriatric patients because of inadequate clinical experience in individuals with severe renal impairment and post-marketing reports of bleeding events. Assessing the degree of anticoagulation may improve the risk:benefit ratio for dabigatran. The aim of this prospective study was to identify whether therapeutic drug monitoring of dabigatran anticoagulant activity using a chromogenic anti-factor IIa assay is a viable option for therapy individualization. Plasma dabigatran concentration was assessed in nine patients with nonvalvular atrial fibrillation aged 75 years or older currently receiving dabigatran etexilate for prevention of stroke, using an anti-factor IIa chromogenic assay and HPLC-MS/MS. Trough concentrations were evaluated on two separate occasions to determine intrapatient variation. Blood was collected at 13.1 ± 2.3 h (mean ± SD) post dose from patients prescribed dabigatran etexilate 150 mg twice daily (5/9 patients) or dabigatran etexilate 75 mg twice daily (4/9 patients). Results from the anti-factor IIa chromogenic assay correlated with dabigatran concentrations as assessed by HPLC-MS/MS (r (2)  = 0.81, n = 16). There was no correlation between dabigatran trough values taken at separate visits (r (2)  = 0.002, n = 7). Furthermore, there was no correlation found between the drug concentrations and patients' renal function determined by both creatinine and cystatin-C based equations. None of the patients enrolled in the study were in the proposed on-therapy trough range during at least one visit. The chromogenic anti-factor IIa assay demonstrated similar performance in quantifying dabigatran plasma trough concentrations to HPLC-MS/MS. Single measurement of dabigatran concentration by either of two methods during routine visits may not be reliable in identifying patients at consistently low or high dabigatran concentrations.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Slovenia 1 10%
Unknown 9 90%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 30%
Professor 2 20%
Student > Ph. D. Student 2 20%
Lecturer 1 10%
Unspecified 1 10%
Other 1 10%
Readers by discipline Count As %
Medicine and Dentistry 6 60%
Unspecified 3 30%
Pharmacology, Toxicology and Pharmaceutical Science 1 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2016.
All research outputs
#3,972,985
of 7,672,691 outputs
Outputs from Thrombosis Journal
#53
of 93 outputs
Outputs of similar age
#145,382
of 267,457 outputs
Outputs of similar age from Thrombosis Journal
#3
of 4 outputs
Altmetric has tracked 7,672,691 research outputs across all sources so far. This one is in the 28th percentile – i.e., 28% of other outputs scored the same or lower than it.
So far Altmetric has tracked 93 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,457 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.